NEW YORK (GenomeWeb News) – Epigenomics today announced it has submitted the third of four modules to US regulators for possible approval of its Epi proColon blood-based colorectal cancer screening test.

The German molecular diagnostics company said it expects to submit the fourth and final module to the US Food and Drug Administration in the second half of this year.